StreetInsider.com News Articles

UBS Assumes Natera (NTRA) at Buy

Wed, 09 Sep 2026 06:08:55 -0400

UBS analyst Douglas Schenkel assumes coverage on Natera (NASDAQ: NTRA) with a Buy rating and a price target of $435.00.

For an analyst ratings summary and ratings history on Natera click here. For more ratings news on Natera click here.

Shares of Natera closed at $324.14 yesterday.

Rothschild Redburn Starts Natera (NTRA) at Buy

Tue, 08 Sep 2026 03:26:41 -0400

Rothschild Redburn analyst Jamie Clark initiates coverage on Natera (NASDAQ: NTRA) with a Buy rating and a price target of $385.00.

The analyst comments: “Natera is the market leader in MRD testing with its Signatera tumour-informed test. It also offers Latitude, a tumour-naïve MRD test in CRC, and is developing an MCED screening test. It also offers pre-natal testing and hereditary screening. We launch with a Buy rating, based on its leadership position in MRD and its ongoing data generation to support additional reimbursement. We forecast a 22% 2026-29E revenue CAGR, with profitability improving gradually as the company continues to invest

Rothschild Redburn Starts Natera (NTRA) at Buy

Tue, 08 Sep 2026 03:26:41 -0400

Rothschild Redburn analyst Jamie Clark initiates coverage on Natera (NASDAQ: NTRA) with a Buy rating and a price target of $385.00.

Natera (NTRA) PT Raised to $376 at Baird

Thu, 03 Sep 2026 07:06:17 -0400

Baird analyst Catherine Ramsey Schulte raised the price target on Natera (NASDAQ: NTRA) to $376.00 (from $348.00) while maintaining a Outperform rating.

Form 4 Natera, Inc. For: Aug 06 Filed by: Fesko John

Fri, 28 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260828/26999441.html

Form 4 Natera, Inc. For: Aug 06 Filed by: Fesko John

Fri, 28 Aug 2026 21:35:00 -0400

si-local-file:///var/storage/secattach/20260828/26999441.html

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera’s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including breast cancer. This growing

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

Fri, 28 Aug 2026 11:03:00 -0400

The partnership combines Natera's leadership in breast cancer research and personalized molecular residual disease (MRD) testing with Susan G. Komen's global advocacy and patient support network

Natera partners with Angiex to monitor cancer drug trial with ctDNA test

Thu, 27 Aug 2026 06:01:49 -0400

Natera, Inc. (NASDAQ: NTRA) announced a collaboration with Angiex, Inc. to use Natera's Signatera test in a Phase I clinical trial of AGX101, an investigational cancer treatment being developed by Angiex.

Angiex is enrolling patients with unresectable, locally advanced, or metastatic solid tumors in the trial. AGX101 is a TM4SF1-directed antibody-drug conjugate designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated endothelial cells.

Under the collaboration, Natera's Signatera test will be used for longitudinal circulating tumor DNA (ctDNA) monitoring during AGX101 treatment. The companies said the testing is intended to explore whether ctDNA measurements can complement

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

Thu, 27 Aug 2026 06:00:00 -0400

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs).

Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach is intended to address both tumor cells and tumor vasculature.